FDA Broadens Pathway for Rare Disease Treatments with New Approval – The Wall Street Journal

  1. FDA expands pathway for rare disease treatments with new approvalThe Wall Street Journal
  2. RETA Stock Soars as FDA Approves Reata Phama’s Neurological Drug | Investor Business DailyInvestor Business Daily
  3. Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxiabusiness thread
  4. FDA approves Reata’s treatment for rare neurological conditionSTAT
  5. Reata Pharmaceuticals up 192% on approval of Friedreich’s ataxia drug omaveloxolone (RETA)Looking for Alpha
  6. See full coverage on Google News

Leave a Comment

Your email address will not be published. Required fields are marked *